These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 6531436)
21. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. Baker GB; Coutts RT; McKenna KF; Sherry-McKenna RL J Psychiatry Neurosci; 1992 Nov; 17(5):206-14. PubMed ID: 1362653 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. Fagervall I; Ross SB Biochem Pharmacol; 1986 Apr; 35(8):1381-7. PubMed ID: 2870717 [TBL] [Abstract][Full Text] [Related]
23. Relationship between the pharmacological and biochemical properties of a monoamine oxidase inhibitor preferentially affecting 5-hydroxytryptamine oxidation. Christmas AJ; Hall DW; Hayward A; Maxwell DR Br J Pharmacol; 1970 May; 39(1):207P-208P. PubMed ID: 5420104 [No Abstract] [Full Text] [Related]
24. A comparison of the effects of chronic administration of tranylcypromine and phenelzine on rat brain levels of the catecholamines and their O-methylated metabolites. Baker JM; Baker GB; Coutts RT; LeGatt DF Proc West Pharmacol Soc; 1983; 26():361-4. PubMed ID: 6889365 [No Abstract] [Full Text] [Related]
25. Monoamine oxidase inhibitors: nature of their interaction with rabbit pancreatic islets to alter insluin secretion. Feldman JM; Chapman B Diabetologia; 1975 Dec; 11(6):487-94. PubMed ID: 1107123 [TBL] [Abstract][Full Text] [Related]
33. Elevation of rat brain tyrosine levels by phenelzine is mediated by its active metabolite β-phenylethylidenehydrazine. Matveychuk D; Nunes E; Ullah N; Aldawsari FS; Velázquez-Martínez CA; Baker GB Prog Neuropsychopharmacol Biol Psychiatry; 2014 Aug; 53():67-73. PubMed ID: 24607770 [TBL] [Abstract][Full Text] [Related]
34. Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. Marley E; Wozniak KM J Psychiatr Res; 1984; 18(2):191-203. PubMed ID: 6235366 [TBL] [Abstract][Full Text] [Related]
35. Effect of nonselective and selective inhibitors of monoamine oxidases A and B on pethidine toxicity in mice. Boden R; Botting R; Coulson P; Spanswick G Br J Pharmacol; 1984 May; 82(1):151-4. PubMed ID: 6428496 [TBL] [Abstract][Full Text] [Related]
36. [Effect of monoamine oxidase inhibitors on the tryptamine content of the rat brain and on "tryptamine convulsions"]. Popov N; Lietz W; Matthies H Acta Biol Med Ger; 1967; 18(2):233-44. PubMed ID: 5586804 [No Abstract] [Full Text] [Related]
37. Monoamine receptor sensitivity changes following chronic administration of MDL 72394, a site-directed inhibitor of monoamine oxidase. Palfreyman MG; Mir AK; Kubina M; Middlemiss DN; Richards M; Tricklebank MD; Fozard JR Eur J Pharmacol; 1986 Oct; 130(1-2):73-89. PubMed ID: 3780861 [TBL] [Abstract][Full Text] [Related]
38. Effects of repeated lithium administration on the subcellular distribution of 5-hydroxytryptamine in rat brain. Atterwill CK; Tordoff AF Br J Pharmacol; 1982 Jul; 76(3):413-21. PubMed ID: 7104517 [TBL] [Abstract][Full Text] [Related]
39. Monoamine oxidase inhibitors: effects on tryptophan concentrations in rat brain. Sherry-McKenna RL; Wong JT; Paetsch PR; Baker GB; Mousseau DD; McKenna KF; Coutts RT; Greenshaw AJ J Neural Transm Suppl; 1994; 41():155-63. PubMed ID: 7931222 [TBL] [Abstract][Full Text] [Related]
40. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement. Celada P; Pérez J; Alvarez E; Artigas F J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]